While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Lilly has taken a non-exclusive license to deploy Dexcom’s CGM systems – which include app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the ...

The platform could provide an alternative to the "artificial pancreas" systems, which use glucose-sensing devices coupled with insulin pumps. Lilly would likely have been right at the top of the ...

The settlement requires Novo Nordisk to offer its insulin products ... reached with Eli Lilly and Sanofi. 13 Noodle Recipes to Celebrate Chinese New Year Tesla's Heat Pump: A Game-Changer for ...

They say over the past two-plus decades, they’ve overpaid millions of dollars for insulin through their employees’ health plans. So, they’re suing the manufacturers including Lilly ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...

Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection. If Eli Lilly has its way, this may be the future of obesity care.